Monday, August 24

Browsing: tlnwon

Hanmi Pharm signs 3.2 tln-won licensing deal with Roche’s Genentech for obesity drug candidate

By healthylife7August 24, 20260

Aug. 24 (Yonhap) — Hanmi Pharm. Co., a South Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won (US$2.3 billion) licensing deal with Genentech Inc., a U.S.-based member of the Roche Group, for an obesity drug candidate designed to reduce body fat while preserving and increasing muscle mass

What's Hot

As Hanmi Pharmaceutical has achieved the feat of exporting up to $2.3 billion (about 3.1723 trillion..

One Too Many campaign encourages healthier relationships with alcohol

Home health insurance, more support for vulnerable patients

Browsing: tlnwon

Hanmi Pharm signs 3.2 tln-won licensing deal with Roche’s Genentech for obesity drug candidate

As Hanmi Pharmaceutical has achieved the feat of exporting up to $2.3 billion (about 3.1723 trillion..

One Too Many campaign encourages healthier relationships with alcohol

Home health insurance, more support for vulnerable patients

Usage of GLP-1 drugs has Surged Rising Over 100 Percent from 2022 to 2024 | News Radio 1200 WOAI

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

What do the Middle Ages tell us about mental health then and now? VCU historian Leigh Ann Craig has answers

Fitness

As Hanmi Pharmaceutical has achieved the feat of exporting up to $2.3 billion (about 3.1723 trillion..

One Too Many campaign encourages healthier relationships with alcohol

Home health insurance, more support for vulnerable patients

Health

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

Subscribe to Updates

What's Hot

Browsing: tlnwon